Development of a novel radiotheranostic platform with a DOTA-based trifunctional chelating agent†
Abstract
Radiotheranostics has attracted attention as a powerful strategy for treating cancer patients with precision medicine. We designed and synthesized a novel DOTA-based trifunctional agent, ADIBO-DOTADG-ALB (ADA), which allowed compounds with targeting ligands, radiometals, and an albumin binder to be readily prepared. ADA exhibited promising properties as a theranostic platform.